Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

<p>Spotlight on brodalumab in the treatment of plaque psoriasis: the evidence to date</p>
Marco Galluzzo, S. D’Adamio, Antonio Massaro, et al.
Clinical Cosmetic and Investigational Dermatology (2019) Vol. Volume 12, pp. 311-321
Open Access | Times Cited: 24

Showing 24 citing articles:

Paradoxical eruptions to targeted therapies in dermatology: A systematic review and analysis
Michael J. Murphy, Jeffrey M. Cohen, Matthew D. Vesely, et al.
Journal of the American Academy of Dermatology (2020) Vol. 86, Iss. 5, pp. 1080-1091
Closed Access | Times Cited: 92
Interactions between neutrophils and T-helper 17 cells
Xinzou Fan, Panyin Shu, Ying Wang, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 25
Immune cells in the epithelial immune microenvironment of psoriasis: emerging therapeutic targets
Lisha Li, Jiaye Lu, Jun Liu, et al.
Frontiers in Immunology (2024) Vol. 14
Open Access | Times Cited: 15
Anti IL-17 in psoriasis
Karen Ly, Mary Patricia Smith, Quinn Thibodeaux, et al.
Expert Review of Clinical Immunology (2019) Vol. 15, Iss. 11, pp. 1185-1194
Closed Access | Times Cited: 75
Biologic Therapies Decrease Disease Severity and Improve Depression and Anxiety Symptoms in Psoriasis Patients
Teodora-Larisa Timiș, Lehel Beni, Teodora Mocan, et al.
Life (2023) Vol. 13, Iss. 5, pp. 1219-1219
Open Access | Times Cited: 15
Candida infections in patients with psoriasis and psoriatic arthritis treated with interleukin-17 inhibitors and their practical management
Carmen Rodríguez‐Cerdeira, José Luís González-Cespón, Erick Martínez‐Herrera, et al.
Italian Journal of Dermatology and Venereology (2021) Vol. 156, Iss. 5
Closed Access | Times Cited: 32
Safety concerns with current treatments for psoriasis in the elderly
Roberta Di Caprio, Giuseppina Caiazzo, Sara Cacciapuoti, et al.
Expert Opinion on Drug Safety (2020) Vol. 19, Iss. 4, pp. 523-531
Closed Access | Times Cited: 30
Brodalumab: A Review of Safety.
Sina Rusta‐Sallehy, Melinda Gooderham, Kim Papp
PubMed (2018) Vol. 23, Iss. 2, pp. 1-3
Closed Access | Times Cited: 24
Eczematous Drug Eruptions
Amy E. Blum, Susan Burgin
American Journal of Clinical Dermatology (2021) Vol. 22, Iss. 3, pp. 349-366
Closed Access | Times Cited: 18
Exploring IL-17 in spondyloarthritis for development of novel treatments and biomarkers
Solveig Skovlund Groen, Dovilė Sinkevičiūtė, Anne‐Christine Bay‐Jensen, et al.
Autoimmunity Reviews (2021) Vol. 20, Iss. 3, pp. 102760-102760
Open Access | Times Cited: 17
An Overview of Contemporary and Future Therapeutic Strategies for Scalp Psoriasis
B. K. Soni, Riya Shivgotra, Karan Trehan, et al.
Current Drug Targets (2024) Vol. 25, Iss. 5, pp. 353-373
Closed Access | Times Cited: 2
Targeting cytokines and signaling molecules related to immune pathways in atopic dermatitis: therapeutic implications and challenges
Hyung-Ook Kim
Archives of Pharmacal Research (2022) Vol. 45, Iss. 12, pp. 894-908
Closed Access | Times Cited: 9
The safety of anti-interleukins monoclonal antibodies for the treatment of psoriasis
S. D’Adamio, Dionisio Silvaggio, Paolo Lombardo, et al.
Expert Opinion on Drug Safety (2019) Vol. 18, Iss. 11, pp. 1031-1041
Closed Access | Times Cited: 14
Long‐term safety of brodalumab in Japanese patients with plaque psoriasis: An open‐label extension study
Yukie Yamaguchi, Nobumichi Takatsu, Kenji Ootaki, et al.
The Journal of Dermatology (2020) Vol. 47, Iss. 6, pp. 569-577
Open Access | Times Cited: 13
Review of secukinumab‐induced adverse events of special interest and its potential pathogenesis
Jingyao Liang, Sanquan Zhang, Qian Li, et al.
Dermatologic Therapy (2022) Vol. 35, Iss. 8
Open Access | Times Cited: 8
The safety of ixekizumab in psoriasis drug therapy
L. Puig
Expert Opinion on Drug Safety (2019) Vol. 19, Iss. 2, pp. 117-130
Closed Access | Times Cited: 13
Real world experience of brodalumab treatment in patients with moderate‐to‐severe plaque psoriasis in the Greek population: Results from an interim analysis of the BrIDGE study
Dimitrios Rigopoulos, Charalampos Angelakopoulos, Zoé Apalla, et al.
Dermatologic Therapy (2022) Vol. 35, Iss. 12
Open Access | Times Cited: 6
Eczematous eruption after brodalumab successfully treated with guselkumab and dupilumab
Matteo Megna, Lucia Genco, Matteo Noto, et al.
Dermatologic Therapy (2022) Vol. 35, Iss. 11
Open Access | Times Cited: 4
Drug survival of brodalumab is greater in patients with psoriasis and psoriatic arthritis in a real‐world setting
Vasiliki Gkanti, Μaria Dalamaga, Evangelia Papadavid
International Journal of Dermatology (2022) Vol. 62, Iss. 1
Closed Access | Times Cited: 3
Safety assessment of brodalumab: Real world adverse event analysis from the FAERS database
Yue Wan, Yang Zhou, Wenjin Chen, et al.
Research Square (Research Square) (2024)
Open Access
Time to Loss of Response following Withdrawal of Ixekizumab in Patients with Moderate-to-Severe Psoriasis
Kim Papp, C. Paul, C. Elise Kleyn, et al.
Acta Dermato Venereologica (2022) Vol. 102, pp. adv00672-adv00672
Open Access | Times Cited: 2
Adrenal Insufficiency Secondary to Abrupt Dose Reduction of Topical Corticosteroid Therapy after Starting Brodalumab for Psoriasis: A Case Report
Mariko Yamane, Hiroaki Hayashi, Yumi Aoyama
Case Reports in Dermatology (2022) Vol. 14, Iss. 1, pp. 77-83
Open Access | Times Cited: 2
A Case of Grover’s Disease Secondary to Brodalumab Therapy for Psoriasis
Sonal Muzumdar, Arash Radfar, Michael Payette
Journal of Psoriasis and Psoriatic Arthritis (2020) Vol. 6, Iss. 1, pp. 16-18
Closed Access
Author reply to: Comment on: ‘Eczematous drug eruption in patients with psoriasis under anti-interleukin-17A: does interleukin-22 play a key role?’
Angelo Ruggiero, Matteo Megna, Giuseppina Caiazzo, et al.
Clinical and Experimental Dermatology (2022) Vol. 48, Iss. 4, pp. 396-397
Closed Access
Page 1

Scroll to top